Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2024 Results Conference Call August 8, 2024 8:15 AM ET
Company Participants
Jing Marantz - Chief Medical Officer
Mo Qatanani - Chief Scientific Officer
Jay Backstrom - Chief Executive Officer
Conference Call Participants
Michael Yee - Jefferies
David Nierengarten - Wedbush Securities
Etzer Darout - BMO Capital Markets
Tessa Romero - JPMorgan
Gary Nachman - Raymond James
Srikripa Devarakonda - Truist Securities
Jay Backstrom
Thank you, Sandra. Good morning and welcome to our Scholar Rock's Second Quarter 2024 Business Update. On behalf of our team, I'd like to thank you for joining our call.
Turning to Slide 4, the focus of today's call is to highlight our exciting progress in 2024. After my introductory remarks, Jing Marantz, our Chief Medical Officer, will provide an update on our development programs, including a review of the 48-month data from TOPAZ apitegromab. Phase 2 proof of concept study followed by Mo Qatanani, our Chief Scientific Officer, who will review the progress with our SRK-439 program in obesity. I'll close with a summary of upcoming milestones, and then open the call up for questions.
Moving to Slide 5, we've made terrific progress over the first half of 2024 and we're on track to achieve all of our key milestones on time or ahead of schedule. The progress with our SMA program has allowed us to continue to advance toward commercialization. Our goal that is coming closer into view for our lead product apitegromab. As we remain on track to report the top-line results for SAPPHIRE, our Phase 3 registration study in Q4. Thanks to the focus and dedication of our study team and the incredible support from our investigators, their clinical study teams and the families participating in SAPPHIRE, we are now only a few months away.
At Scholar Rock, selectivity was foundational to our approach in designing apitegromab. And is the hallmark of our differentiated platform. Our research team has been incredibly productive and has delivered and continues to deliver a portfolio of potential medicines that are highly differentiated and with best-in-class potential. We focused our industry-leading anti-myostatin programs in areas where we believe we can make substantial advances in care, creating new possibilities for those living with SMA and with obesity, high-value therapeutic areas that provide unique opportunities to fuel our growth. It is an exciting time at Scholar Rock. We are at a point in our trajectory where the next 12 months to 24 months will be transformative.